Adamax: The Complete Guide

Adamax is an investigational seven-amino-acid peptide. The molecule is built from two parents: Semax (an ACTH(4–7) analog from the Russian Academy of Sciences, registered in Russia as a nasal nootropic since the late 1990s) and P21 (a CNTF-derived peptidomimetic from the Iqbal lab at NYS-IBR, with an adamantyl cap that improves brain penetration and proteolytic stability). Adamax fuses the Semax core with that adamantyl cap.

The name causes confusion. Some vendors call it a Khavinson adrenal bioregulator with sequence Lys-Glu-Asp-Trp (KEDW). That’s wrong on both counts. KEDW belongs to Pancragen, a different compound that targets the pancreas. And the “Ada-” in Adamax refers to the adamantyl chemistry — not to adrenal anything. There is no Khavinson-group paper on Adamax in any database.

Regulatory status

• FDA, EMA: not approved.
• Russia: the parent Semax is registered as a nasal solution. Adamax itself is not registered as a drug or supplement.
• New Zealand Medsafe: identified in border seizures of designer drugs and recommended for prescription-medicine scheduling — one of the few formal regulatory citations of Adamax anywhere.
• WADA 2026: not listed by name. Athletes should not assume it’s permitted — as an ACTH(4–10)-derived peptide it could plausibly fall under S2.4 (Corticotrophins) and the S0 catch-all for non-approved substances applies. Consult your governing body.

The honest answer up front: nobody has measured what Adamax does in humans or animals. The molecule has not been studied in indexed primary research. The mechanism story is built entirely by adding what the two parents do separately.

From the Semax side, the parent literature shows indirect BDNF and NGF upregulation in rat hippocampus, modest dopamine modulation that only emerges in the presence of stimuli (not at baseline), and immune gene-expression effects in rat focal-ischemia models. Notably, the ACTH(4–10) family was specifically designed not to activate the HPA axis — that piece of ACTH is the behavioral fragment, not the adrenocortical one. Vendor framing of Adamax as “regulating stress hormones” or “modulating cortisol” isn’t supported by the parent biology.

From the P21 side, the proposed pathway is BDNF / TrkB / PI3K / Akt activation, with downstream effects on dentate-gyrus neurogenesis, synaptic plasticity, and tau hyperphosphorylation in 3xTg-AD mouse models. The adamantyl cap improves blood-brain-barrier penetration and metabolic stability. P21 has been carried into preclinical development by Phanes Biotech for Alzheimer’s, but no human trial has been published.

Vendor pages typically claim Adamax does all of the above, plus dual MC3R/MC4R activation with preferential MC4R binding. None of those claims has been measured for the Adamax molecule itself. The most accurate framing is: Adamax probably behaves like Semax plus P21 in animals. That’s an inference, not a measurement.

Every “benefit” in vendor copy is borrowed from the parent peptides. Here’s the honest read on each:

• Cognitive enhancement and focus — the Semax Russian clinical literature supports this in stroke recovery and cognitive disorders; nothing measured in healthy users on Adamax specifically.
• BDNF upregulation — established in P21 mouse data; never directly measured on Adamax.
• Neuroprotection — supported in P21 Alzheimer’s mouse models; preclinical only.
• Stroke recovery — the Semax Russian-registered indication; not tested on Adamax.
• Tau-pathology reduction — P21/P021 in 3xTg-AD mice; preclinical only.
• HPA / cortisol / stress-hormone modulation — no evidence in either direction. The vendor framing here isn’t supported.

One specific misattribution worth flagging: the recent CDKL5 deficiency paper (Frasca et al. 2024, J Neurodev Disord) shows up in some vendor copy as Adamax evidence. It’s a P021 paper, not an Adamax paper.

No human trial has established a dose for Adamax. The ranges below come from vendor protocols and community practice, not validated research.

Route	Common Range	Frequency
Intranasal spray	200–600 µg/spray, 1–3 sprays/day	Daily, morning
Subcutaneous injection	300–1000 µg/day	Daily, morning
Oral / sublingual	Poorly defined	Daily

Two cycle patterns appear in community use: continuous 4–12 weeks followed by a break, or 5 days on / 2 days off across longer runs. Intranasal is the most common route — it mirrors how Semax is dosed in its Russian-registered form. Avoid late-day dosing; insomnia is the most consistent community-reported side effect.

Standard SC peptide reconstitution. For a typical 10 mg lyophilized vial: add 2 mL bacteriostatic water for a final concentration of 5 mg/mL (5000 µg/mL). On a U-100 insulin syringe, 1 unit = 50 µg — so a 500 µg dose is 10 units, and a 1000 µg dose is 20 units.

Lyophilized vials are stable at room temperature short-term; refrigerate for longer storage. Once reconstituted, refrigerate and use within 28 days (the standard BAC water beyond-use date). Nasal solutions should be refrigerated and protected from light.

For the full reconstitution protocol, see the Bacteriostatic Water guide.

There’s no published safety data on Adamax — no FAERS, EudraVigilance, or Yellow Card entries. Community reports parallel the parent Semax profile:

• Insomnia, especially with afternoon or evening dosing. The most consistent report.
• Mild stimulation; some users describe Adamax as “more stimulating than Semax.”
• Nasal irritation with the intranasal route.
• Mild injection-site reactions with SC dosing.
• Mild headache, often in the first week.

The adamantyl modification doesn’t add documented toxicity from peptide-class data. The adamantyl-amine antivirals (amantadine, rimantadine) are different chemistry and their side-effect profiles don’t apply here.

• Pregnancy or breastfeeding — no safety data.
• History of seizure disorder — theoretical concern from BDNF/TrkB pathway activation. Not measured for Adamax.
• Active malignancy with TrkB-expressing tumor types (some neuroblastomas, glioblastomas, certain lung and breast adenocarcinomas).
• Concurrent high-dose stimulants (amphetamines, modafinil, high caffeine) — insomnia and sympathomimetic stack risk.
• Active hypertension — no data; the ACTH-fragment lineage warrants caution.
• Athletes subject to anti-doping testing — consult your governing body before use.

Three confusions come up regularly:

Adamax is not Pancragen. Some sources frame Adamax as the Khavinson tetrapeptide KEDW (Lys-Glu-Asp-Trp). KEDW is a real Khavinson peptide — but it’s Pancragen, which targets the endocrine pancreas. It has nothing to do with Adamax.

Adamax is not a Khavinson adrenal product. The closest thing in the Khavinson family is Glandokort (A-17), an oral bovine-adrenal polypeptide extract sold as a Russian supplement. Glandokort isn’t a synthetic short peptide, has zero indexed papers, and isn’t Adamax. The Khavinson naming convention is real (Cartalax → cartilage, Pancragen → pancreas), but Adamax isn’t in that family at all.

The “Ada-” in Adamax means adamantyl, not adrenal. It refers to the chemical-modification group at the C-terminus, copied from P21.

Adjacent compounds people sometimes lump in: Semax (parent #1, Russian-registered nasal nootropic), P21/P021 (parent #2, Iqbal-lab preclinical Alzheimer’s candidate), N-Acetyl Semax and N-Acetyl Semax Amidate (related modifications without the adamantyl cap), Selank (sister Russian peptide, GABAergic anxiolytic mechanism), and Cerebrolysin (porcine brain extract). Each is a distinct molecule with its own pharmacology.